EGFR and mucoepidermoid carcinoma: Tyrosine kinase inhibitor (TKI) therapy was reported with partial response in cases both with and without EGFR mutation for pulmonary MEC.[12,13] Despite this, the role of TKI therapy in MEC remains unclear, especially in those patients who had a response to TKI therapy but had no activating EGFR mutations in their tumors.